BioSpace News Archive

Business

Neogen Announces Fourth-Quarter 2023 Results

Neogen Corporation announced today the results of the fourth quarter and fiscal year ended May 31, 2023.

July 27, 2023
·
17 min read
Business

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development.

July 27, 2023
·
6 min read
Business

Natera to Report its Second Quarter 2023 Results on August 3rd

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023.

July 27, 2023
·
1 min read
Revvity Signals Software and Scitara Expand Strategic Relationship to Accelerate Laboratory Digital Transformation

Today, Revvity announced that its Revvity Signals Software business has entered into a strategic relationship with Scitara

July 27, 2023
·
4 min read
Business

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

Xencor, Inc. today announced it will release second quarter 2023 financial results after the market closes on Thursday, August 3, 2023.

July 27, 2023
·
1 min read
Business

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

Wave Life Sciences Ltd. will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 3, 2023, to review the company’s second quarter 2023 financial results and provide business updates.

July 27, 2023
·
1 min read
Deals

Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network

Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of AMCR Institute, which has been in operation for more than 20 years.

July 27, 2023
·
3 min read
Drug Development

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

UroGen Pharma Ltd. (Nasdaq: URGN) today announced positive topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

July 27, 2023
·
9 min read
Pharm Country

TriRx Partnership with Liverpool City Region Advances Biotech Capabilities

TriRx Pharmaceutical Services, LLC, a Contract Development and Manufacturing Organization, welcomed the UK Government’s recent announcement on England’s second Investment Zone, focused on Life Sciences in the Liverpool City Region.

July 27, 2023
·
2 min read
Biotech Beach

n-Lorem Has Industrialized the Treatment of Nano-rare Patients and Formed Key Committees

n-Lorem, a nonprofit foundation , outlines the steps the Foundation has taken to support the discovery, development and treatment of nano-rare patients (1-30 patients worldwide), for free, for life.

July 27, 2023
·
4 min read